Fennec Pharmaceuticals (FENC) Stock Price, News & Analysis

-0.14 (-1.49%)
(As of 04/23/2024 ET)
Today's Range
50-Day Range
52-Week Range
288,706 shs
Average Volume
114,180 shs
Market Capitalization
$250.40 million
P/E Ratio
Dividend Yield
Price Target

Fennec Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
87.6% Upside
$17.33 Price Target
Short Interest
9.07% of Float Sold Short
Dividend Strength
News Sentiment
0.16mentions of Fennec Pharmaceuticals in the last 14 days
Based on 12 Articles This Week
Insider Trading
Selling Shares
$1.96 M Sold Last Quarter
Proj. Earnings Growth
From $0.11 to $0.70 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.41 out of 5 stars

Medical Sector

474th out of 910 stocks

Biological Products, Except Diagnostic Industry

73rd out of 153 stocks

FENC stock logo

About Fennec Pharmaceuticals Stock (NASDAQ:FENC)

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

FENC Stock Price History

FENC Stock News Headlines

Exposed: 10 CENT Crypto to Explode April 20th?
Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than Bitcoin
Exposed: 10 CENT Crypto to Explode April 20th?
Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than Bitcoin
Fennec Pharmaceuticals Inc (NASDAQ:FENC) Short Interest Update
Q4 2023 Fennec Pharmaceuticals Inc Earnings Call
FENC Apr 2024 12.500 call
See More Headlines
Receive FENC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fennec Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
3 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$21.25 million
Book Value
($0.43) per share


Free Float
Market Cap
$250.40 million
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

FENC Stock Analysis - Frequently Asked Questions

Should I buy or sell Fennec Pharmaceuticals stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Fennec Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" FENC shares.
View FENC analyst ratings
or view top-rated stocks.

What is Fennec Pharmaceuticals' stock price target for 2024?

3 analysts have issued 12-month target prices for Fennec Pharmaceuticals' stock. Their FENC share price targets range from $16.00 to $18.00. On average, they predict the company's stock price to reach $17.33 in the next year. This suggests a possible upside of 87.6% from the stock's current price.
View analysts price targets for FENC
or view top-rated stocks among Wall Street analysts.

How have FENC shares performed in 2024?

Fennec Pharmaceuticals' stock was trading at $11.22 at the beginning of 2024. Since then, FENC stock has decreased by 17.6% and is now trading at $9.24.
View the best growth stocks for 2024 here

Are investors shorting Fennec Pharmaceuticals?

Fennec Pharmaceuticals saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 1,810,000 shares, an increase of 7.1% from the March 15th total of 1,690,000 shares. Based on an average daily trading volume, of 110,600 shares, the days-to-cover ratio is currently 16.4 days. Currently, 9.1% of the company's shares are short sold.
View Fennec Pharmaceuticals' Short Interest

When is Fennec Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our FENC earnings forecast

How were Fennec Pharmaceuticals' earnings last quarter?

Fennec Pharmaceuticals Inc (NASDAQ:FENC) posted its quarterly earnings results on Thursday, March, 21st. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by $0.12. The firm had revenue of $9.74 million for the quarter, compared to analyst estimates of $9.47 million.

What guidance has Fennec Pharmaceuticals issued on next quarter's earnings?

Fennec Pharmaceuticals updated its FY 2023 earnings guidance on Thursday, February, 29th. The company provided EPS guidance of for the period. The company issued revenue guidance of $20.7 million-$21.2 million, compared to the consensus revenue estimate of $19.6 million.

What other stocks do shareholders of Fennec Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fennec Pharmaceuticals investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Pfizer (PFE), Amarin (AMRN), VBI Vaccines (VBIV), Gilead Sciences (GILD), Trevena (TRVN), Aldeyra Therapeutics (ALDX), Coherus BioSciences (CHRS) and Exelixis (EXEL).

How do I buy shares of Fennec Pharmaceuticals?

Shares of FENC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:FENC) was last updated on 4/23/2024 by Staff

From Our Partners